Now showing items 1-6 of 6

    • An Anti-HIV-1 V3 Loop Antibody Fully Protects Cross-Clade and Elicits T-Cell Immunity in Macaques Mucosally Challenged with an R5 Clade C SHIV 

      Hemashettar, Girish; Wang, Wendy; Novembre, Francis J.; Villinger, Francois; Ibegbu, Chris; Patel, Kalpana; Corti, Davide; Agatic, Gloria; Vanzetta, Fabrizia; Bianchi, Siro; Heeney, Jonathan L.; Sallusto, Federica; Lanzavecchia, Antonio; Watkins, Jennifer D; Siddappa, Nagadenahalli B.; Lakhashe, Samir; Humbert, Michael; Sholukh, Anton M; Wong, Yin Ling; Yoon, John C.; Ruprecht, Ruth Margrit (Public Library of Science, 2011)
      Neutralizing antibodies have been shown to protect macaques against SHIV challenge. However, genetically diverse HIV-1 clades have evolved, and a key question left unanswered is whether neutralizing antibodies can confer ...
    • Identification and Characterization of a Broadly Cross-Reactive HIV-1 Human Monoclonal Antibody That Binds to Both gp120 and gp41 

      Zhang, Mei-Yun; Yuan, Tingting; Rosa Borges, Andrew; Guenaga, Javier; Yang, Zheng; Wang, Yanping; Li, Yuxing; Polonis, Victoria R.; Pincus, Seth H.; Dimitrov, Dimiter S.; Li, Jingjing; Watkins, Jennifer D; Ruprecht, Ruth Margrit; Wilson, Richard (Public Library of Science, 2012)
      Identification of broadly cross-reactive HIV-1-neutralizing antibodies (bnAbs) may assist vaccine immunogen design. Here we report a novel human monoclonal antibody (mAb), designated m43, which co-targets the gp120 and ...
    • Isolation of Monoclonal Antibodies with Predetermined Conformational Epitope Specificity 

      Sholukh, Anton M.; Mukhtar, Muhammad Mahmood; Humbert, Michael; Essono, Sosthène S.; Watkins, Jennifer D.; Vyas, Hemant Kumar; Shanmuganathan, Vivekanandan; Hemashettar, Girish; Kahn, Maria; Hu, Shiu-Lok; Montefiori, David C.; Polonis, Victoria R.; Schur, Peter Henry; Ruprecht, Ruth Margrit (Public Library of Science, 2012)
      Existing technologies allow isolating antigen-specific monoclonal antibodies (mAbs) from B cells. We devised a direct approach to isolate mAbs with predetermined conformational epitope specificity, using epitope mimetics ...
    • Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose 

      Sholukh, Anton M; Byrareddy, Siddappa N; Shanmuganathan, Vivekanandan; Hemashettar, Girish; Lakhashe, Samir K; Rasmussen, Robert A; Watkins, Jennifer D; Vyas, Hemant K; Thorat, Swati; Brandstoetter, Tania; Mukhtar, Muhammad M; Yoon, John K; Novembre, Francis J; Villinger, Francois; Landucci, Gary; Forthal, Donald N; Ratcliffe, Sarah; Tuero, Iskra; Robert-Guroff, Marjorie; Polonis, Victoria R; Bilska, Miroslawa; Montefiori, David C; Johnson, Welkin E; Ertl, Hildegund C; Ruprecht, Ruth M (BioMed Central, 2014)
      Background: A key goal for HIV-1 envelope immunogen design is the induction of cross-reactive neutralizing antibodies (nAbs). As AIDS vaccine recipients will not be exposed to strains exactly matching any immunogens due ...
    • Passive immunization with polyclonal anti-SHIV IgG: partial protection or increased acquisition of heterologous tier 2 SHIV – depending on IgG dose 

      Sholukh, Anton M; Siddappa, NB; Shanmuganathan, V; Lakhashe, Samir; Rasmussen, Robert Anthony; Watkins, Jennifer D; Vyas, Hemant Kumar; Mukhtar, Muhammad Mahmood; Hemashettar, G; Thorat, Swati; Yoon, JK; Villinger, F; Novembre, FJ; Landucci, G; Forthal, DN; Ratcliffe, S; Robert-Guroff, M; Polonis, V; Montefiori, DC; Ertl, HC; Ruprecht, Ruth Margrit (BioMed Central, 2012)
    • R5 Clade C SHIV Strains with Tier 1 or 2 Neutralization Sensitivity: Tools to Dissect Env Evolution and to Develop AIDS Vaccines in Primate Models 

      Wassermann, Klemens J.; Song, Ruijiang; Wang, Wendy; Kramer, Victor G.; Novembre, Francis J.; Villinger, François; Else, James G.; Montefiori, David C.; Watkins, Jennifer D; Siddappa, Nagadenahalli B.; Lakhashe, Samir; Santosuosso, Michael Robert; Poznansky, Mark; Rasmussen, Robert Anthony; Ruprecht, Ruth Margrit (Public Library of Science, 2010)
      Background: HIV-1 clade C (HIV-C) predominates worldwide, and anti-HIV-C vaccines are urgently needed. Neutralizing antibody (nAb) responses are considered important but have proved difficult to elicit. Although some current ...